ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.-Reference-Cited by-同舟云学术

ESPAC-4: A multicenter, international, open-label randomized controlled phase III trial of adjuvant combination chemotherapy of gemcitabine (GEM) and capecitabine (CAP) versus monotherapy gemcitabine in patients with resected pancreatic ductal adenocarcinoma.

Published:2016-05-20 Issue:15_suppl Volume:34 Page:LBA4006-LBA4006
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Neoptolemos John P.¹,Palmer Dan¹,Ghaneh Paula¹,Valle Juan W.²,Cunningham David³,Wadsley Jonathan⁴,Meyer Tim⁵,Anthoney Alan⁶,Glimelius Bengt⁷,Falk Stephen⁸,Segersvard Ralf⁹,Izbicki Jakob R.¹⁰,Middleton Gary William¹¹,Ross Paul J.¹²,Wasan Harpreet¹³,Mcdonald Alec¹⁴,Crosby Tom David Lewis¹⁵,Psarelli Eftychia Eirini¹,Hammel Pascal¹⁶,Buchler Markus W.¹⁷

Affiliation:

1. University of Liverpool, Liverpool, United Kingdom;

2. Department of Medical Oncology, The Christie NHS Foundation Trust; University of Manchester, Manchester, United Kingdom;

3. Royal Marsden Hospital, Surrey, United Kingdom;

4. Weston Park Hospital, Sheffield, United Kingdom;

5. UCL Cancer Institute, University College London,, London, United Kingdom;

6. Leeds Cancer Research UK Clinical Centre, Leeds, United Kingdom;

7. Uppsala University, Uppsala, Sweden;

8. Bristol Haematology and Oncology Centre, Bristol, United Kingdom;

9. Karolinska Institute, Stockholm, Sweden;

10. University Medical Center Hamburg-Eppendorf, Hamburg, Germany;

11. University of Birmingham, Surrey, United Kingdom;

12. Guy's Hospital, London, United Kingdom;

13. Hammersmith Hospital, Imperial College, London, United Kingdom;

14. Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom;

15. Velindre Cancer Centre, Cardiff, United Kingdom;

16. Hôpital Beaujon, Clichy, France;

17. University of Heidelberg, Heidelberg, Germany;

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

http://ascopubs.org/doi/pdfdirect/10.1200/JCO.2016.34.15_suppl.LBA4006

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Prognosis Value of PIWIL1 and PIWIL2 Expression in Pancreatic Cancer;Journal of Clinical Medicine;2019-08-22

2. Pancreatic Cancer and Possible Therapeutic Options;Breaking Tolerance to Pancreatic Cancer Unresponsiveness to Chemotherapy;2019

3. Evolution of Pancreatic Cancer Surgery;Pancreatic Cancer;2017

4. Clinical practice guidelines — what is the evidence?;Nature Reviews Clinical Oncology;2016-08-17